araag2/HINT huggingface dataset:
Clinical trial NCT02422446 (phase 3, status: terminated)
Conditions: type 2 diabetes, coronary artery disease
ICD codes: E11.65, E11.9, E11.21, E11.36, E11.41, E11.42, E11.44, I25.10, I25.110, I25.119, I25.111, I25.118
Drugs: icosapent ethyl
SMILES: CCOC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CC
Reason stopped: 
    difficulty enrolling patients with elevated triglycerides under statin treatment
  
Eligibility criteria:

        Inclusion Criteria:

          -  Age 30+ years

          -  Hypertriglyceridemia (150-400 mg/dl)

          -  Statin use for at least six months at the time of screening

          -  Type 2 diabetes treated with diet and/or oral hypoglycemic agents diagnosed 1+ year

          -  Ability to provide informed consent and provide blood samples

          -  Willingness to abstain from fish oil, EPA, over the counter niacin, and other omega-3
             fatty acid supplements during the study period (12 weeks)

          -  Ability to travel to the study site at Brigham and Women's Hospital for 3 study visits

          -  Reactive hyperemia index (RHI) of ≤ 2.0

        Exclusion Criteria:

          -  Eating disorder or heavy drinkers

          -  Treatment with chronic prescription pharmacotherapy for metabolic or cardiovascular
             disease management or risk factor modification

          -  Pregnant or lactating women

          -  Statin use <6 months at the time of screening

          -  Allergy to EPA, fish oil, or other omega-3 fatty acids

          -  Current use of insulin, cyclophosphamide, estrogen, fibrates, niacin, hormone
             replacement therapy, testosterone, oral contraceptives, growth hormones, insulin-like
             growth factor-1, and other systemic steroids.

          -  Inability to provide informed consent or blood samples

          -  History or prevalent diagnosis of cancer, asthma, kidney insufficiency, stroke,
             seizures, allergic disorders, or congestive heart failure

          -  Diagnosis of diabetes < 1 year prior to enrollment

          -  Intention to move out of greater Boston area within one year

          -  Current use of omega-3 supplements, fish oil, or >2 servings of fish per week

          -  Bleeding disorder or uncontrolled endocrine (i.e., thyroid) or metabolic disorders

          -  Treatment with blood thinning drugs (i.e. warfarin and clopidogrel)

          -  Major surgical operation 3 months before or after screening

          -  Organ transplantation

          -  Current participation in another trial or plan to do so during the study

          -  Inability to give informed consent or to travel to the study center at Brigham and
             Women's Hospital

          -  RHI of >2.0

          -  Triglycerides <150 mg/dl or >400 mg/dl

          -  Body mass index of 40+ kg/m2
Clinical trial NCT02425644 (phase 3, status: completed)
Conditions: multiple sclerosis
ICD codes: G35, C81.18
Drugs: ponesimod, teriflunomide
SMILES: CCC\N=C1/S\C(=C/C2=CC=C(OC[C@H](O)CO)C(Cl)=C2)C(=O)N1C1=CC=CC=C1C, C\C(O)=C(/C#N)C(=O)NC1=CC=C(C=C1)C(F)(F)F
Eligibility criteria:

        Inclusion Criteria:

        Male and female subjects aged 18 to 55 years with established diagnosis of MS McDonald 2010
        with relapsing course from onset (i.e., RRMS and SPMS with superimposed relapses).

        Subjects must have active disease evidenced by one or more MS attacks with onset within the
        period of 12 to 1 months prior to randomization, or by two or more MS attacks with onset
        within the 24 to 1 months prior to randomization, or with one or more gadolinium-enhancing
        (Gd+) lesion(s) of the brain on an MRI performed within 6 months prior to randomization.

        Enrolled subjects must be ambulatory (EDSS score of up to 5.5 inclusive) and may be
        treatment-naïve or previously treated with MS disease modifying therapy.

        Exclusion Criteria:

        Subjects with significant medical conditions or therapies for such conditions (e.g.,
        cardiovascular, pulmonary, immunological, hepatic,ophthalmological conditions) or lactating
        or pregnant women are not eligible to enter the study.

        Subjects with contraindications to MRI or with clinically relevant medical or surgical
        conditions that, in the opinion of the investigator, would put the subject at risk by
        participating in the study are not eligible to enter the study.
Clinical trial NCT02425891 (phase 3, status: active, not recruiting)
Conditions: triple negative breast cancer
ICD codes: C79.81, D24.1, D24.2, D24.9, D49.3, C44.501, D48.60
Drugs: atezolizumab (mpdl3280a), an engineered anti-pdl1 antibody, nab-paclitaxel, placebo
SMILES: CCCNCC(O)COC1=C(C=CC=C1)C(=O)CCC1=CC=CC=C1, [H][C@]12[C@H](OC(=O)C3=CC=CC=C3)[C@]3(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)C4=CC=CC=C4)C4=CC=CC=C4)C(C)=C([C@@H](OC(C)=O)C(=O)[C@]1(C)[C@@H](O)C[C@H]1OC[C@@]21OC(C)=O)C3(C)C, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Metastatic or locally advanced, histologically documented TNBC characterized by
             absence of human epidermal growth factor 2 (HER2), estrogen receptor (ER), and
             progesterone receptor (PR) expression

          -  No prior chemotherapy or targeted systemic therapy for inoperable locally advanced or
             metastatic TNBC

          -  Eligible for taxane monotherapy (i.e., absence of rapid clinical progression,
             life-threatening visceral metastases, or the need for rapid symptom and/or disease
             control)

          -  A representative formalin-fixed, paraffin-embedded tumor specimen in paraffin blocks,
             or at least 20 unstained slides with an associated pathology report documenting ER,
             PR, and HER2 negativity. Participants with fewer than 20 unstained slides available at
             baseline, and not fewer than 12 unstained slides will be eligible upon discussion with
             Medical Monitor

          -  Eastern Cooperative Oncology Group performance status of 0 or 1

          -  Measurable disease as defined by RECIST v1.1

          -  Adequate hematologic and end-organ function

        Exclusion Criteria:

          -  Known central nervous system (CNS) disease, except for treated asymptomatic CNS
             metastases

          -  Leptomeningeal disease

          -  Pregnancy or lactation

          -  History of autoimmune disease

          -  Prior allogeneic stem cell or solid organ transplantation

          -  Positive test for human immunodeficiency virus

          -  Active hepatitis B or hepatitis C

          -  Receipt of a live, attenuated vaccine within 4 weeks prior to randomization, during
             treatment, or within 5 months following the last dose of atezolizumab/placebo
Clinical trial NCT02427893 (phase 3, status: withdrawn)
Conditions: melanoma
ICD codes: C43.0, C43.31, D03.9, C43.51, C43.9, D03.0, C43.4
Drugs: cobimetinib, vemurafenib
SMILES: OC1(CN(C1)C(=O)C1=C(NC2=C(F)C=C(I)C=C2)C(F)=C(F)C=C1)[C@@H]1CCCCN1, CCCS(=O)(=O)NC1=C(F)C(C(=O)C2=CNC3=NC=C(C=C23)C2=CC=C(Cl)C=C2)=C(F)C=C1
Reason stopped: 
    no patients were enrolled
  
Eligibility criteria:

        Inclusion Criteria:

          -  Signed informed consent

          -  Signed HIV testing consent

          -  Life expectancy ≥ 12 weeks

          -  Able to swallow pills

          -  ECOG performance status 2 or less

          -  Adequate bone marrow function

          -  Adequate renal function

          -  Adequate liver function

          -  Negative urine pregnancy test within 7 days prior to commencement of dosing in
             premenopausal women

          -  Histological diagnosis of unresectable AJCC stage III or stage IV, BRAFV600E/K mutant
             melanoma

          -  Measurable disease

          -  Accessible tumor that can be biopsied

          -  Naive to targeted therapy (Prior immune-based therapy in the adjuvant setting or for
             advanced disease will be allowed if >2 weeks from study entry)

        Exclusion Criteria:

          -  Active systemic infection

          -  Active autoimmune disease or history of known or suspected autoimmune disease

          -  Active brain metastases or leptomeningeal metastases

          -  Treatment with any immunomodulatory medication within 4 weeks of initiation of study
             therapy.

          -  Positive test for hepatitis B virus

          -  Positive test for hepatitis C virus

          -  Positive test for human immunodeficiency virus (HIV)

          -  Pregnant, lactating or breast feeding women

          -  Localized radiation therapy within the last 14 days

          -  History of malabsorption

          -  No consumption of the following within 7 days prior to start of treatment:

               -  St. John's wort or hyperforin (potent cytochrome P450 CYP3A4 enzyme inducer)

               -  Grapefruit juice (potent cytochrome P450 CYP3A4 enzyme inhibitor

          -  History or evidence of cardiovascular risk

          -  History or evidence of retinal pathology
Clinical trial NCT02431247 (phase 3, status: completed)
Conditions: immunodeficiency virus type 1, human
ICD codes: D84.9, D81.9, D83.9, D84.821, B20, D82.2, D84.822
Drugs: darunavir/cobicistat/emtricitabine/tenofovir alafenamide fdc, drv/cobi fdc, ftc/tdf fdc, d/c/f/taf fdc - matching placebo, ftc/tdf fdc matching placebo, drv/cobi fdc matching placebo
SMILES: [H][C@@](C)(CN1C=NC2=C(N)N=CN=C12)OCP(=O)(OCOC(=O)OC(C)C)OCOC(=O)OC(C)C, CC(C)OC(=O)[C@H](C)N[P@](=O)(CO[C@H](C)CN1C=NC2=C(N)N=CN=C12)OC1=CC=CC=C1, [H][C@@](C)(CN1C=NC2=C(N)N=CN=C12)OCP(=O)(OCOC(=O)OC(C)C)OCOC(=O)OC(C)C, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Subject must be antiretroviral (ARV) treatment-naive (never treated with an ARV
             including post-exposure prophylaxis and pre-exposure prophylaxis); no prior use of any
             approved or experimental anti- human immunodeficiency virus (anti-HIV) drug for any
             length of time

          -  Screening plasma HIV-1 ribonucleic acid (RNA) level greater than or equal to >=1,000
             copies per milliliter (copies/mL)

          -  Cluster of Differentiation 4+ (CD4+) cell count >50 cells/microliter (cells/mcL)

          -  Screening HIV-1 genotype report must show full sensitivity to DRV, TDF and FTC

          -  Screening eGFRcreatinine >=70 mL/min according to the Cockcroft-Gault formula for
             creatinine clearance

        Exclusion Criteria:

          -  Subject has been diagnosed with a new acquired immunodeficiency syndrome
             (AIDS)-defining condition within the 30 days prior to screening

          -  Subject has proven or suspected acute hepatitis within 30 days prior to screening

          -  Subject is hepatitis C or hepatitis B positive

          -  Subject has a history of cirrhosis
Clinical trial NCT02434328 (phase 3, status: completed)
Conditions: neovascular age-related macular degeneration, choroidal neovascularization
ICD codes: H35.3211, H35.3212, H35.3221, H35.3222, H35.3231, H35.3232, H35.3291, H44.2A1, H44.2A2, H44.2A3, H44.2A9, H35.3231, H35.3232, H35.3211
Drugs: brolucizumab ophthalmic solution, aflibercept ophthalmic solution
SMILES: N[C@@H](CCCNC(N)=N)C(O)=O
Eligibility criteria:

        Key Inclusion Criteria:

          -  Provide written informed consent;

          -  Active CNV lesions secondary to AMD that affected the central subfield in the study
             eye at Screening;

          -  Total area of CNV > 50% of the total lesion area in the study eye at Screening;

          -  Intraretinal and/or subretinal fluid affecting the central subfield of the study eye
             at Screening;

          -  Best corrected visual acuity (BCVA) between 78 and 23 letters, inclusive, in the study
             eye at Screening and Baseline using Early Treatment Diabetic Retinopathy Study (ETDRS)
             testing.

        Key Exclusion Criteria:

          -  Any active intraocular or periocular infection or active intraocular inflammation in
             either eye at Baseline;

          -  Central subfield of the study eye affected by fibrosis or geographic atrophy or total
             area of fibrosis ≥ 50% of the total lesion in the study eye at Screening;

          -  Subretinal blood affecting the foveal center point and/or ≥ 50% of the lesion of the
             study eye at Screening;

          -  Any approved or investigational treatment for neovascular age-related macular
             degeneration (nAMD) in the study eye at any time;

          -  Retinal pigment epithelial rip/tear in the study eye at Screening or Baseline or
             current vitreous hemorrhage or history of vitreous hemorrhage in the study eye within
             4 weeks prior to Baseline;

          -  Pregnant or nursing women; women of child-bearing potential;

          -  Stroke or myocardial infarction in the 6-month period prior to Baseline.
Clinical trial NCT02436096 (phase 3, status: completed)
Conditions: fibromyalgia, myofascial pain syndromes, muscular diseases, musculoskeletal diseases, nervous system diseases, neuromuscular diseases, rheumatic diseases
ICD codes: M79.7, G71.00, G71.02, G71.11, G12.9, G71.09, N36.44, G12.1, Z82.69, Z87.39, G31.9, B57.40, B57.49, G37.9, G37.3, G13.1, G09, M41.40, M41.42, M41.43, M41.44, M41.45, M41.46, M41.47, I09.9, I01.8, I01.9, I05.9, I06.9, I07.9, I08.9
Drugs: tnx-102 sl tablet, 2.8mg, placebo sl tablet
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Diagnosis of Primary Fibromyalgia (2010 ACR criteria)

          -  Male or female 18-75 years old

          -  For patients with major depressive disorders only: clinically stable, no suicidal risk
             and stable anti-depressant therapy

          -  Willing and able to withdraw specific therapies (ask PI)

          -  Medically acceptable form of contraception (female only)

          -  Signed informed consent

        Exclusion Criteria:

          -  Arthritis, lupus and other systemic auto-immune diseases

          -  Regional or persistent pain that could interfere with assessment of fibromyalgia pain

          -  Bipolar and psychotic disorders

          -  Increased risk of suicide

          -  Significant clinical (cardiac, systemic infection, systemic corticosteroid
             requirement, drug/alcohol abuse) or laboratory abnormalities.

          -  Unability to wash-out specific medications (ask PI)

          -  Known hypersensitivity to cyclobenzaprine

          -  Others: seizure disorders, severe/untreated sleep apnea, BMI>40
Clinical trial NCT02436512 (phase 3, status: withdrawn)
Conditions: pulmonary arterial hypertension
ICD codes: I27.21
Drugs: inhaled nitric oxide
SMILES: OC[C@H]1O[C@H]([C@H](O)[C@@H]1O)N1C=NC2=C1NC=NC2=O
Reason stopped: 
    inability meet enrollment in study population.
  
Eligibility criteria:

        Inclusion Criteria:

          -  The subject or subject's legally authorized representative signs and dates an
             Institutional Review Board (IRB) approved informed consent form prior to the
             initiation of any study-related activities.

          -  The subject has been diagnosed with PAH (WHO Group 1) and is WHO Functional Class I or
             II at Screening.

          -  The subject has documented continuous PGI use for ≥ 1 year from Screening, without a
             significant interruption (i.e., ≤ 2 day interruption) and without a failed complete
             wean attempt.

          -  The subject is a candidate for weaning off parenteral PGI therapy (per Investigator
             judgment and standard of care).

        Exclusion Criteria

          -  The subject has a hypersensitivity or allergy to ingredients of inhaled nitric oxide
             or other clinically significant allergies (clinical significance per Investigator
             judgment).

          -  The subject has a PCWP or left ventricular end diastolic pressure (LVEDP) ≥15 mmHg at
             Baseline.

          -  The subject has participated in an investigational product or device study within the
             30 days prior to Screening.
Clinical trial NCT02436668 (phase 3, status: completed)
Conditions: metastatic pancreatic adenocarcinoma
ICD codes: C22.0, C22.1, C4A.9, C7B.1, D09.9, C4A.0, C4A.31
Drugs: ibrutinib, gemcitabine, nab-paclitaxel
SMILES: NC1=NC=NC2=C1C(=NN2[C@@H]1CCCN(C1)C(=O)C=C)C1=CC=C(OC2=CC=CC=C2)C=C1, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, [H][C@]12[C@H](OC(=O)C3=CC=CC=C3)[C@]3(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)C4=CC=CC=C4)C4=CC=CC=C4)C(C)=C([C@@H](OC(C)=O)C(=O)[C@]1(C)[C@@H](O)C[C@H]1OC[C@@]21OC(C)=O)C3(C)C
Eligibility criteria:

        Inclusion Criteria:

          1. Histologically or cytologically confirmed diagnosis of pancreatic adenocarcinoma.

          2. Stage IV disease diagnosed within 6 weeks of randomization

          3. Adequate hematologic function:

               -  Absolute neutrophil count (ANC) ≥1.5 x 109/L

               -  Platelet count ≥100 x 109/L

               -  Hemoglobin ≥9 g/dL

          4. Adequate hepatic and renal function defined as:

               -  AST and/or ALT ≤5.0 x upper limit of normal (ULN) if liver metastases, or ≤3 x
                  ULN without liver metastases

               -  Alkaline phosphatase <3.0 x ULN or ≤5.0 x ULN if liver or bone metastases present

               -  Bilirubin ≤1.5 x ULN (unless bilirubin rise is due to Gilbert's syndrome or of
                  non-hepatic origin, such as hemolysis)

               -  Estimated Creatinine Clearance ≥30 mL/min

          5. PT/INR <1.5 x ULN and PTT (aPTT) <1.5 x ULN

          6. KPS ≥70.

          7. Eastern Cooperative Oncology Group (ECOG) 0-1

        Exclusion Criteria:

          1. Prior therapies: BTK inhibitor, radiotherapy, radiotherapy in the adjuvant setting, or
             cytotoxic chemotherapy for primary disease of pancreatic adenocarcinoma.

          2. Neuroendocrine (carcinoid, islet cell) or acinar pancreatic carcinoma

          3. Known brain or leptomeningeal disease (CT or MRI scan of the brain required only in
             case of clinical suspicion of central nervous system involvement).

          4. Major surgery within 4 weeks of first dose of study drug.

          5. History of stroke or intracranial hemorrhage within 6 months prior to enrollment.

          6. Treatment with a strong cytochrome P450 (CYP) 3A inhibitor.
Clinical trial NCT02438007 (phase 3, status: terminated)
Conditions: prostate cancer
ICD codes: C61, D29.1, D40.0, Z15.03, Z80.42, Z85.46, Z12.5
Drugs: galeterone, enzalutamide
SMILES: [H][C@@]12CC=C(N3C=NC4=CC=CC=C34)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC=C2C[C@@]([H])(O)CC[C@]12C, CNC(=O)C1=C(F)C=C(C=C1)N1C(=S)N(C(=O)C1(C)C)C1=CC=C(C#N)C(=C1)C(F)(F)F
Eligibility criteria:

        Inclusion Criteria:

          -  Progressive metastatic (M1) disease on androgen deprivation therapy

          -  Detectable AR-V7 from circulating tumors (CTCs)

          -  ECOG performance status 0 or 1

        Exclusion Criteria:

          -  Prior treatment with second generation anti-androgens (e.g. abiraterone, enzalutamide)

          -  Prior treatment with chemotherapy for CRPC
Clinical trial NCT02438826 (phase 3, status: completed)
Conditions: chronic cluster headache
ICD codes: G44.021, G44.029
Drugs: galcanezumab 300 mg, placebo
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Participants with a history of chronic cluster headache occurring without a remission
             period, or with remissions lasting <1 month, for at least 1 year.

          -  Participants are able to distinguish cluster headache attacks from other headaches.

        Exclusion Criteria:

          -  Current enrollment in or discontinuation within the last 30 days from, a clinical
             trial involving any investigational drug or device.

          -  Current use or any prior exposure to any calcitonin-gene-related peptide (CGRP)
             antibody, any antibody to the CGRP receptor, or antibody to nerve growth factor (NGF).

          -  Are taking indomethacin and/or are suspected of having another distinct trigeminal
             autonomic cephalalgia.

          -  A history of migraine variants that could implicate or could be confused with
             ischemia.

          -  Known hypersensitivity to multiple drugs, monoclonal antibodies or other therapeutic
             proteins.

          -  A history or presence of other medical illness that indicates a medical problem that
             would preclude study participation.

          -  Evidence of significant active or unstable psychiatric disease, in the opinion of the
             investigator.

          -  Women who are pregnant or nursing.
Clinical trial NCT02450890 (phase 3, status: unknown status)
Conditions: attention deficit hyperactivity disorder
ICD codes: F90.2, F90.8, F90.9, F90.0, F90.1
Drugs: placebo first, then oradur®, oradur® first, then placebo
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Main inclusion criteria:

          1. Female or male subjects with age between 6 and 18 years old.

          2. Subjects with documented diagnosis of one of the three presentations of Attention
             Deficit Hyperactivity Disorder (ADHD) within one year by investigator assessment using
             Diagnostic & Statistical Manual for Mental Disorders-Fifth Edition (DSM-5).

          3. Both subjects and parents/guardians have provided their signed and dated informed
             consent form for the study.

        Main exclusion criteria:

          1. Subjects have received ADHD treatment for over 1 year or those who have received other
             ADHD treatment within 30 days prior to the study treatment initiation.

          2. By investigator's evaluation, subjects are very anxious, tense or agitated.

          3. Subjects known to be allergic to any ORADUR®-methylphenidate ingredients.

          4. Subjects with an estimated intelligence quotient (IQ) < 80.

          5. Subjects are taking a concomitant medication (ex: Monoamine Oxidase Inhibitor (MAOI))
             that is likely to interfere with safe administration of methylphenidate within 14 day
             prior to the study treatment initiation.

          6. Subjects are joining other clinical studies and receiving any other investigational
             medical products within 30 days prior to the study treatment initiation.

          7. Subjects have glaucoma (narrow angle glaucoma), on-going seizure disorder, or other
             psychotic disorder.

          8. Subjects have chronic tics, Tourette's syndrome, or a family history of Tourette's
             syndrome.

          9. Subjects have clinically significant gastrointestinal problems, including narrowing of
             the gastrointestinal tract.

         10. Subjects/caregivers are (in the case of subjects whose parents/caregivers were to fill
             out the study questionnaires) with drug or alcohol abuse/dependence within the prior 6
             months.

         11. By the investigators' discretion, subjects with serious or unstable medical illness
             that will interfere with the evaluations of study efficacy and safety.

         12. In the investigators' opinion, subjects cannot understand or follow the instructions
             given in the study.

         13. Psychological, familial, sociological, or geographical condition potentially hampering
             compliance with the study protocol and follow-up schedule.